Weekly Analysts’ Ratings Changes for Spruce Biosciences (SPRB)

A number of firms have modified their ratings and price targets on shares of Spruce Biosciences (NASDAQ: SPRB) recently:

• 8/17/2026 – Spruce Biosciences had its “buy” rating reaffirmed by Guggenheim. They now have a $104.00 price target on the stock, down from $123.00.
• 8/15/2026 – Spruce Biosciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/13/2026 – Spruce Biosciences was upgraded by The Goldman Sachs Group, Inc. to “overweight”.
• 8/13/2026 – Spruce Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Spruce Biosciences had its price target lowered by Citizens Jmp from $150.00 to $144.00. They now have a “market outperform” rating on the stock.
• 8/12/2026 – Spruce Biosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/13/2026 – Spruce Biosciences is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $160.00 price target on the stock.

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.